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To study the beneficial effects of ivabradine in dilated cardiomyopathy (DCM) mice,
which evolved from coxsackievirus B3-induced chronic viral myocarditis. Four-to-five-
week-old male balb/c mice were inoculated intraperitoneally with coxsackievirus B3
(Strain Nancy) on days 1, 14, and 28. The day of the first virus inoculation was
defined as day 1. Thirty-five days later, the surviving chronic viral myocarditis mice
were divided randomly into two groups, a treatment group and an untreated group.
Ivabradine was administered by gavage for 30 consecutive days in the treatment
group, and the untreated group was administered normal saline. Masson’s trichrome
stain was used to evaluate the fibrosis degree in myocardial tissue. The expression
levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6),
collagen I, collagen III and p38-MAPK signaling pathway proteins were detected by
Western blot. Electrocardiogram was used to investigate the heart rate and rhythm.
The thickness of the ventricular septum and left ventricular posterior wall, left ventricular
end diastolic dimension, left ventricular end systolic dimension, left ventricular ejection
fractions and fractional shortening were studied by echocardiography. Compared with
the untreated chronic viral myocarditis mice, ivabradine significantly increased the
survival rate, attenuated the myocardial lesions and fibrosis, improved the impairment of
the left ventricular function, diminished the heart dimension, decreased the production
of collagen I and collagen III, reduced the expression of the proinflammatory cytokines
TNF-α, IL-1β, and IL-6, and lowered the production of phospho-p38 MAPK. The findings
indicate the therapeutic effect of ivabradine in preventing the progression from viral
myocarditis to DCM in mice with chronic viral myocarditis induced by coxsackievirus
B3, is associated with inhibition of the p38 MAPK pathway, downregulated inflammatory
responses and decreased collagen expression. Ivabradine appears a promising
approach for the treatment of patients with viral myocarditis.
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INTRODUCTION
Coxsackievirus B3 (CVB3), considered one of the most
widespread causative factors of viral myocarditis, induced more
than half of the cases of acute myocarditis and one-fourth of
the cases of dilated cardiomyopathy (DCM) (Henke et al., 2003).
Acute viral myocarditis would evolve to the chronic stage if there
is no effective treatment, and the worst outcome is DCM and
chronic heart failure (HF), even cardiac sudden death.
The heart rate (HR) has been shown to be directly related to
the risk of cardiovascular disease, HF, and mortality (Opasich
et al., 2001). An elevated HR might limit ventricular diastolic
filling and increase myocardial oxygen demand. In addition,
an increased HR is known to be associated with systemic
inflammation and cytokines (Sajadieh et al., 2004). Several
experimental studies (Sajadieh et al., 2004; Fox et al., 2008; Perret-
Guillaume et al., 2009) have demonstrated that inflammation
has a close relationship with HR. With an increased HR,
inflammation would be aggravated, and the cardiovascular death
rate and hospital admissions because of HF are significantly
increased (Sajadieh et al., 2004; Fox et al., 2008; Dominguez-
Rodriguez et al., 2012; O Hartaigh et al., 2013).
Ivabradine (IVA), a selective If channel inhibitor affecting the
sinus node, inhibits the pacemaker current and reduces the HR
without affecting blood pressure, cardiac contractility and the
conduction system (Swedberg et al., 2010). IVA has a beneficial
effect in patients with HF (Custodis et al., 2008; Walcher
et al., 2010; Dominguez-Rodriguez et al., 2012). Several studies
have reported that ivabradine might play a protective role in
cardiovascular inflammation. Becher et al. (2012) suggested that
ivabradine reduced the expression of cytokines in hypertensive
HF, reduced cardiac collagen accumulation and eliminated
cardiac fibrosis. Recently, we demonstrated that ivabradine
decreased the HR and the expression of pro-inflammatory
cytokines and provided protection in a murine model of acute
viral myocarditis (Yue-Chun et al., 2012; Li et al., 2013). However,
the protective role of ivabradine in DCM caused by chronic viral
myocarditis remains unclear. Therefore, in the present study, we
investigated if ivabradine attenuated inflammation and prevented
the progression from viral myocarditis to DCM in mice with
chronic viral myocarditis induced by coxsackievirus B3.
MATERIALS AND METHODS
Chronic Viral Myocarditis Model
One hundred and fifty 4–5-week-old, male Balb/c mice were
purchased from the Shanghai Laboratory Animal Central, China.
The mice were first randomly assigned to three groups: normal
control group 1 (CON-35, n = 10), normal control group 2
(CON-65, n= 10), and chronic viral myocarditis group (CVMC,
n = 130). All mice in the CON-35 and CON-65 groups were
killed on days 35 and 65, respectively. The CVMC group mice
were inoculated intraperitoneally with 100 TCID50 CVB3 (strain
Nancy) 0.2, 0.25, and 0.3 ml on days 1, 14, and 28, respectively.
We defined the day of the first virus inoculation as day 1. The
normal control mice were inoculated intraperitoneally with an
equivalent dose of Eagle’s MEM. CVB3 was provided by the
American Type Culture Collection (ATCC). The development
of chronic viral myocarditis and DCM was assessed, and seven
mice from the chronic viral myocarditis group were killed on
day 35 (CVMC-35, n = 7). Then, the remaining surviving
chronic myocarditis mice in the CVMC group were divided
into two groups randomly on day 35: an untreated chronic
viral myocarditis group (CVMC-65, n = 35) and an ivabradine
treatment group (IVA, n = 20). The treatment group was treated
by intragastric administration with ivabradine (5 mg/kg per day)
for 30 days consecutively, and the untreated group mice were
given a gavage of normal saline of the same volume. IVA was
obtained from Servier Co (Courbevoie, France). The doses were
selected according to previous experiments (Yue-Chun et al.,
2012; Li et al., 2013). The experimental design is shown in
Figure 1. The study conformed to the China Animal Protection
Law. The Wenzhou Medical University Committee on Ethics in
the Use and Care of Laboratory Animals approved the conduct of
this study.
Electrocardiogram
The mice were anesthetized intraperitoneally with 4% chloral
hydrate (0.02 ml/g) before recording. HR and rhythm were
recorded by a Labchat electrocardiogram (ECG) recorder, which
was provided by Wenzhou Medical University. ECG was
recorded for 1 min continuously.
Echocardiogram
A Sonos 5500 ultrasound machine (Phillips, USA) was used to
perform the transthoracic echocardiography, as described in our
previous publications (Yue-Chun et al., 2012; Li-Sha et al., 2015).
The mice were anesthetized intraperitoneally with 4% chloral
hydrate (0.02 ml/g). The chest was shaved. The parasternal long-
axis view was recorded by the M-mode and two-dimensional
echocardiographic images. Each of these captured image loops
included 5–10 cardiac cycles, and the data were averaged from
at least three cycles per loop. The thickness of the ventricular
septum and left ventricle posterior wall (LVPW), left ventricular
end-systolic diameter (LVESD), and left ventricular end-diastolic
diameters (LVEDD) were detected for at least five consecutive
cardiac cycles. Then, the left ventricular ejection fraction (LVEF)
and fractional shortening (FS) were calculated. End diastolic or
end systolic was defined as the maximum or minimal LV diastolic
or systolic diameter, respectively.
Survival Rate
At the end of the first stage, on day 35, the survival rate between
the control group and the chronic viral myocarditis group was
compared. At the end of the second stage, on day 65, the
survival rate of the treatment group and the untreated group was
compared after 30 days of treatment with ivabradine.
Myocardial Histopathology and Tissue
Viral Titers
The heart weight (HW), body weight (BW) and the ratio of HW
to BW (HW/BW) were calculated. The heart tissue was fixed in
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FIGURE 1 | Experimental design. CON represents the normal control group. CON-35 and CON-65 represent the normal control groups whose mice were killed
on days 35 and 65, respectively. CVB3 represents the chronic viral myocarditis group.
4% paraformaldehyde, routinely processed, paraffin embedded,
sectioned and stained. Masson’s trichrome stain, a collagen-
specific stain for interstitial fibrosis, was used to quantitatively
estimate the expression of collagen and the fibrosis area. Images
were acquired by a light microscope connected to a digital video
camera (Olympus, Tokyo, Japan). Five sections of each heart
were scored by two observers blindly. The scores assigned to
these specific sections were averaged, as described in our previous
papers (Li-Sha et al., 2015, 2016). The extent of myocardial
fibrosis was graded and scored as follows: 0 = no fibrosis;
1+ = fibrosis involving <25% of the myocardial interstitial;
2+= fibrosis involving 25–50%; 3+= fibrosis involving 50–75%;
and 4+= fibrosis involving 75% to 100%.
The viral titer of the myocardial tissue was estimated
by the Reed–Muench method. Isolated cardiac tissue with
aseptic conditions was washed with Hank’s liquid three times.
Fragmentized myocardial tissue was digested by 0.25% trypsin for
5 min, and then virus maintenance fluid (DMEM: FBS = 98:2)
was added to the digested myocyte suspension. The mixture
was frozen at −20◦C for 2 h and then thawed and shaken for
2 min to release the CVB3 in myocytes completely (repeated
three times). Low temperature high speed centrifugation (4◦C,
8000 r/min, 10 min) and filtration were performed. The Hep2
cell suspension was dropped into a cell culture plate, and the
virus concentration gradient was diluted from 10−1 to 10−7. The
Hep2 cells were cultured in an incubator at 37◦C, 5% CO2 for
2 days.
Western Blot
For the Western blot, proteins were separated on polyacrylamide
gels and transferred to a PVDF membrane for detection with
various antibodies, including primary monoclonal antibodies
for tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β),
interleukin-6 (IL-6), phospho-p38 MAPK (P-p38) and total-
p38 MAPK (T-p38) (Cell Signaling Technology Corporation,
USA) and a polyclonal antibody for collagen I, collagen
III (Biorbyt Corporation, USA). The SDS-PAGE (8 and
12% polyacrylamide gels) method separated the protein, and
electrophoresis (90 min, 80–120 V) and constant current
(300 mA) transfer were used for the Western blots. The
blots were blocked with 5% non-fat milk-TBST for 2 h at
room temperature. The PVDF membrane was gently incubated
overnight at 4◦C with primary antibody (rabbit serum IgG) and
incubated with the secondary antibody (HRP-marked goat anti-
rabbit) for 1 h at room temperature and then exposed with
ECL
Statistical Analysis
Continuous variables are expressed as the mean ± standard
deviation (SD). The survival rate was analyzed by
the Kaplan–Meier method. Categories variables were
performed by rank-sum test. Comparisons between
groups were performed by one-way analysis of variance
(ANOVA), followed by Fisher’s protected least significant
difference test. A value was considered significant with
P < 0.05.
RESULTS
Mouse Model of Chronic Viral
Myocarditis on Day 35
The characteristics of the chronic viral myocarditis mice are
summarized in Table 1. No dead mice were found in the control
group. The total survival rate of the chronic viral myocarditis
mice on day 35 was 47.69% (62/130) (Figure 2A), and the
LVEF in the chronic viral myocarditis mice (CVMC-35) was
significantly lower than that in the normal control mice (CON-
35) (P < 0.05). The expression of collagen and cytokines in the
chronic myocarditis mice on day 35 was higher than that in the
normal control groups (P < 0.05).
The viral titer of myocardial tissue was estimated by
the Reed–Muench method. The virus replication peak in
the cardiac tissue was on days 4 to 7. On day 7 post-
inoculation (p.i), the TCID50 = 10−6.12 ± 0.582; On day
14 p.i, the TCID50 = 10−5.88 ± 0.655; On day 35 p.i, the
TCID50 = 10−3.22 ± 0.653; In the control group, the TCID50 = 0.
Ivabradine did not attenuate the viral titer in the cardiac tissue on
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TABLE 1 | Animal characteristics and cardiac function results.
Variable CON-35 CVMC-35 CON-65 CVMC-65 IVA
Mouse characteristics
Body weight, g 26.42 ± 1.963 19.9 ± 2.96 26.00 ± 3.65 22.09 ± 2.581 24.38 ± 3.70
Heart weight, mg 116.07 ± 7.948 95.32 ± 14.04# 117.7 ± 16.5 112.71 ± 10.50 104.13 ± 17.38
Heart weight/body weight, mg/g 4.40 ± 0.188 4.79 ± 0.193# 4.532 ± 0.197 5.13 ± 0.4521 4.28 ± 0.370#
Cardiac function
Heart rate, bpm 492.2 ± 14.18 550.3 ± 22.52 505.4 ± 18.72 563.5 ± 14.15∗ 412.7 ± 18.271
Septum, mm 0.789 ± 0.018 0.662 ± 0.012 0.8 ± 0.013 0.613 ± 0.065 0.733 ± 0.0263
LVPW, mm 0.771 ± 0.023 0.668 ± 0.017 0.761 ± 0.046 0.654 ± 0.088 0.763 ± 0.0243#
LVEDd, mm 2.185 ± 0.107 2.97 ± 0.081 2.36 ± 0.079 3.637 ± 0.1061 2.389 ± 0.135#
LVESd, mm 1.31 ± 0.09 1.77 ± 0.103 1.46 ± 0.054 2.063 ± 0.185 1.328 ± 0.095#
LVEF, % 82.73 ± 1.66 71.00 ± 2.32 84.84 ± 1.402 66.07 ± 2.411 1 82.24 ± 1.139#
FS, % 44.64 ± 0.455 36.52 ± 0.43 45.09 ± 0.344 34.55 ± 0.4181 40.88 ± 0.807#
CON-35, normal control group 1; CVMC-35, chronic viral myocarditis group; CON-65, normal control group 2; CVMC-65, untreated chronic viral myocarditis group;
IVA, ivabradine treatment group; LVPW, left ventricle posterior wall; LVESd, left ventricular end-systolic diameter; LVEDd, left ventricular end-diastolic diameter; LVEF, left
ventricular ejection fraction; FS, fractional shortening; bpm, beats per minute. #P < 0.05, versus CVMC-65; 1P < 0.05, versus CON-65; P < 0.05, versus CVMC-35;
∗P < 0.05, versus IVA.
day 65 compared with the untreated group (10−1.00 ± 0.091 versus
10−1.76 ± 0.078, P = 0.286) (Figure 2C).
IVA Treatment in Chronic Viral
Myocarditis Mice
Heart Enlargement and Fibrosis of Cardiac Tissue
On day 65, the survival rate of the treatment group (IVA)
was 80.00% (16/20) with ivabradine (5 mg/kg per day) gavage
for 30 days continuously (from day 35 to day 65), whereas
the survival rate of the untreated group (CVMC-65) was
48.57% (17/35) (Figure 2B). Masson’s trichrome stain evaluated
the fibrosis degree of the cardiac tissue (Figures 3A–E). The
scores of myocardial fibrosis in the chronic viral myocarditis
mice were significantly higher than in the CON-35 mice and
the CON-65 mice. With the IVA treatment, the myocarditis
mice showed significantly reduced myocardial fibrosis scores
(P < 0.05). Myocardial fibrosis was increased in the CVMC-65
group compared with the CVMC-35 group. However, there was
no significant difference between the two groups (P = 0.569)
(Figure 3F).
HW/BW Ratio, Heart Rate, and Echocardiographic
Findings
The ratio of HW/BW was calculated. The echocardiographic
findings of the chronic viral myocarditis mice are summarized
in Table 1. As mentioned above, the CVMC-35 group and the
untreated CVMC-65 group had a worse LVEF compared with the
normal control group (P< 0.001), and the LVEF was significantly
decreased (P < 0.05) (Figure 4D).
Ivabradine significantly reduced the ratio of HW/BW
(P < 0.001) and HR (P < 0.01). The HW/BW ratio was
significantly lower in the control groups than in the untreated
CVMC 65 groups on day 65 (P < 0.05) (Figure 4A; Table 1).
The HR of the IVA treatment mice was less than the
control group (P < 0.001) (Figure 4B; Table 1). Ivabradine
significantly enhanced the heart function of myocarditis mice
comprehensively, improved the LVEF and FS (Figure 4D;
FIGURE 2 | The survival rate and cardiac tissue viral titer in CVB3-inoculated mice followed for 35 and 65 days. (A) Survival rate on day 35. The CON-35
group (100%) versus the CVMC-35 group (47.69%). (B) Survival rate on day 65. IVA (80.00%) versus untreated CVMC-65 (48.57%). (C) Viral titer. IVA versus
untreated CVMC-65, P = 0.286.
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FIGURE 3 | Myocardial fibrosis in the heart (Masson’s Trichrome stain). High power lens (40 × 10), fibrosis stained in blue (arrow), cardiac tissue stained in
pink. (A) CON-35; (B) CVMC-35; (C) CON-65; (D) CVMC-65; (E) IVA; (F) Myocardial fibrosis scores. ∗P < 0.05 versus CVMC-65; &P < 0.001 versus CVMC-65;
&&P < 0.001 versus CVMC-35.
FIGURE 4 | Effects of ivabradine on HW/BW, heart rate, cardiac function and myocardial histopathology. (A) HW/BW (The ratio of heart weight to body
weight). #P < 0.05, versus CVMC-65; (B) Heart rate. ∗P < 0.01, versus IVA; 1P < 0.001, versus CON-65; (C) LVEDd (left ventricular end-diastolic diameter).
#P < 0.05, versus CVMC-65; 1P < 0.05, versus CON-65; (D) LVEF (left ventricular ejection fraction). 1P < 0.05, versus CVMC-35; #P < 0.05, versus CVMC-65;
1P < 0.05, versus CON-65.
Table 1). Ivabradine significantly decreased the size of the left
ventricle (Figure 4C; Table 1). The LVEDD in the untreated
CVMC-65 group was significantly larger than that in the control
mice (P< 0.05) (Figure 4C; Table 1). The sizes of the chambers of
the heart in untreated mice were larger than in the IVA treatment
mice, and a thinner left ventricular wall was observed (Table 1).
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Despite the statistically significant difference in LVPW thickness
between the IVA group and the CVMC-65 (P < 0.05), there is no
statistically significant difference in septal wall thickness for these
two groups (P = 0.075).
Ivabradine Reduces the Expression of Collagen and
Cytokines
Pathological sections showed the enlarged chambers in the
chronic viral myocarditis mice, and ivabradine reversed
ventricular remodeling and decreased the size of the heart.
Collagen was the foremost index of fibrosis. Western
blotting indicated that the production of collagen I and
collagen III in the CVMC-35 mice was higher than
that in the normal control group (P < 0.05, P < 0.05)
(Figures 5A,B). The expression levels of collagen I and
collagen III were significantly decreased in the ivabradine
treatment group compared with the untreated group (both
P < 0.05).
As shown in Figures 5C–F, Western blotting revealed that the
expression of cytokines (TNF-α, IL-1β, and IL-6) in the CVMC-
35 group was higher than that in the normal CON-35 group
(all P < 0.05). Ivabradine significantly attenuated the expression
of TNF-α, IL-1β and IL-6 in the treatment group compared
with the untreated group (all P < 0.001). No difference was
found among the CON-65 and IVA groups in the level of IL-1β
(P = 0.181), although there were differences in TNF-α and IL-6
(P < 0.05).
The p38 MAPK Signaling Pathway
The ratio of phospho-p38 MAPK (P-p38) to total-p38 MAPK (T-
p38) was calculated (Figure 6). There was no difference in the
ratio of T-p38/GAPDH among the groups (P > 0.05). The P-p38
level in the CVMC-35 group was higher than that in the CON-35
group (P< 0.001), with the activation of the p38 MAPK signaling
pathway.
The untreated CVMC-65 mice expressed a higher level of
P-p38 than the CON-65 mice (P < 0.001), and ivabradine
significantly attenuated the expression of P-p38 in the treatment
group compared with the untreated group (P < 0.001).
The Progression of Chronic Viral Myocarditis
As the mouse model of chronic viral myocarditis progressed
from day 35 to day 65, we found that there was increased
fibrosis in both the CVMV-35 and CVMC-65 groups. However,
there was no difference between the two groups (P = 0.569)
(Figure 3). In the CVMC-65 mice and CVMC-35 mice, worse
cardiac function occurred. The LVEF in the untreated group was
markedly lower than that in the CVMC-35 group (P < 0.05)
(Table 1). As time passed, no difference was observed in the level
of collagen I between the untreated CVMC-65 and CVMC-35
groups (P = 0.184), although there was a difference in collagen
III (P < 0.001) (Figure 5). No difference was found in the level
of IL-6 between the untreated CVMC-65 and CVMC-35 groups
(P = 0.204), although there were differences in TNF-α and IL-
1β (P < 0.05) (Figure 5). There was no difference between
the untreated CVMC-65 and CVMC-35 groups in the P-p38
expression levels (P = 0.659) (Figure 6).
DISCUSSION
The novel finding of the study is the marked amelioration of
chronic viral myocarditis after treatment with ivabradine in
a CVB3-induced murine chronic myocarditis model. To the
best of our knowledge, this is the first study to investigate
the effects of ivabradine in preventing progression from viral
myocarditis to DCM. In this study, we demonstrated that
ivabradine significantly inhibited the development of chronic
viral myocarditis evolving to DCM. With the ivabradine
treatment, the internal chamber dimension of the left ventricle
was decreased, and both the LVEF and the thickness of the LVPW
were increased markedly in CVB3-infected mice. Ivabradine
significantly improved the survival rate and the impairment
of the left ventricular function in the murine chronic viral
myocarditis model. The findings indicated that ivabradine played
a beneficial role in chronic viral myocarditis. Our previous studies
demonstrated that ivabradine has a therapeutic benefit in an acute
viral myocarditis mouse model (Yue-Chun et al., 2012; Li et al.,
2013). The present study extends the understanding of ivabradine
efficacy in murine viral myocarditis models (Yue-Chun et al.,
2012; Li et al., 2013).
It is well-established that an increased HR is a risk factor
for the development of cardiovascular diseases. HR-controlling
treatments exert several beneficial effects. HR reduction decreases
myocardial oxygen demand and improves endocardial blood
supply. In addition, a prolonged left ventricular diastolic filling
time improves left ventricular filling and inhibits sympathetic
activity (Mulder et al., 2004; Li et al., 2013). In our previous
study (Li et al., 2013) ivabradine significantly decreased the levels
of plasma noradrenaline in mice with acute viral myocarditis
on day 14. In rats with congestive HF, ivabradine significantly
reduced noradrenaline levels on day 90 (Mulder et al., 2004).
These studies indicated that the effect of ivabradine on plasma
noradrenaline was not an acute effect, taking at least 2 weeks to
develop. β-Blockade and the pure bradycardic agent ivabradine
significantly reduced myocardial inflammation in murine acute
viral myocarditis (Yue-Chun et al., 2012; Li et al., 2013; Li-
Sha et al., 2015, 2016). Many experimental and clinical studies
have demonstrated that ivabradine has a beneficial effect on
left ventricular remodeling in the failing heart. In the present
study, ivabradine significantly decreased HR and improved left
ventricular remodeling. We propose that the main mechanism
by which ivabradine exerts these effects is the reduction in HR
because previous animal studies have shown that a reduction
in HR by other means, eg, by ablation of the sinoatrial
node in cynomolgus monkeys, beneficially affects the heart
(Beere et al., 1984; Beere et al., 1992) and most effects of
ivabradine can be reversed by atrial pacing (Heusch, 2008).
However, this compound may have pleiotropic effects beyond HR
reduction (Heusch, 2008). Therefore, long-term HR reduction
induced by ivabradine is a useful target for preventing the
progression toward myocardial dysfunction and preventing
or even reversing remodeling in CVB3-infected chronic viral
myocarditis mice.
Collagen is the main component of extracellular matrix
(ECM). Collagen I and collagen III constitute 90% of the
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FIGURE 5 | Expression of collagens and cytokines in the myocardial tissues of mice on days 35 and 65. (A) Western blot analysis for collagen I and
collagen III. (B) Densitometric analysis of relative protein levels for collagen I and collagen III. 1P < 0.001, 11P < 0.05, IVA versus CVMC-65; &P < 0.05,
&&P < 0.05, versus CON-35; ∗P < 0.001, versus CVMC-65. (C) Western blot analysis for cytokines (TNF-α, IL-1β, and IL-6). (D) Densitometric analysis of relative
protein levels for TNF-α. ∗P < 0.001, versus IVA; ∗∗P < 0.05, versus CON-35; ∗∗∗P < 0.05, versus CON-65; 1P < 0.05, versus CVMC-65. (E) Densitometric
analysis of relative protein levels for IL-β. ∗P < 0.001, versus IVA; ∗∗P < 0.05, versus CON-35; #P < 0.05, versus CVMC-65. (F) Densitometric analysis of relative
protein levels for IL-6. ∗P < 0.001, versus IVA; &P < 0.05, versus CON-65; ∗∗P < 0.05, versus CON-35.
total collagen. The ECM is crucial for the structural integrity
of the heart. Modulation of the balance between ECM-
synthesis and ECM degradation is an important process of
myocardial remodeling and left ventricular function. Moderate
collagen production is a repair process under certain condition
(Midwood et al., 2004; Chen and Raghunath, 2009). When
synthesis exceeds degradation, an adverse accumulation of
collagen appears to distort tissue structure. Its disproportionate
accumulation, in the form of either a reactive or a reparative
fibrosis, further increases stiffness and cardiac remodeling
(Weber et al., 1994; Cohn et al., 2000). The common
pathological basis of chronic viral myocarditis and DCM is
the hyperplasia of collagen in the interstitium. The excessive
accumulation of collagen is an important factor in the
transition of acute myocarditis to DCM (Rutschow et al., 2010;
Westermann et al., 2010). Rutschow et al. (2010) revealed
that viral persistence induces chronic myocardial inflammation
and significantly increases collagen production. Therefore, the
reduction of the excessive collagen production is beneficial
in preventing progression from viral myocarditis to DCM.
In this study, collagen III was significantly increased in the
untreated CVMC-65 mice compared with the untreated CVMC-
35 mice (P < 0.001), although no difference was found in
the expression of collagen I between the untreated CVMC-
35 mice and CVMC-65 mice (P = 0.092). The secretion of
collagen was increased gradually in the process of myocardial
fibrosis, and the longer-term observation (e.g., up to 90 or
120 days after infection) might provide more meaningful
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FIGURE 6 | Expression of p38 MAPK in the myocardial tissues of mice on days 35 and 65. (A) Western blot analysis for phospho-p38 MAPK (P-p38) and
total-p38 MAPK (T-p38). (B) Densitometric analysis of relative protein levels for P-p38/ T-p38. ∗∗P < 0.001, versus CON-35; ∗∗∗P < 0.001 versus untreated CVMC-
65; ∗P < 0.001 versus CON-65.
data for collagen I. Collagen I and collagen III measured by
Western blot were significantly decreased in the ivabradine
treatment mice compared with the untreated CVMC-65 mice,
which was consistent with the Masson’s Trichrome stain
findings. With the treatment of ivabradine, the degree of
fibrosis measured by Masson’s trichrome stain was significantly
reduced (P < 0.05). A previous study (Rutschow et al., 2010)
revealed that the high collagen content was associated with
the development of left ventricular dysfunction and dilation
in chronic viral myocarditis mice. In this study, ivabradine
remarkably prevented the progression from viral myocarditis
to DCM with myocardial collagen reduction. Echocardiography
showed that the LVEF was significantly decreased in the
CVMC-35 group compared with the CON-35 mice. On day
65, the LVEF was significantly decreased and the LVEDD
was significantly increased in the CVMC-65 group compared
with the CON-65 group. A lower LVEF was found in the
untreated CVMC-65 group compared with the CVMC-35 group
(P < 0.001). However, ivabradine significantly increased the
LVEF (P < 0.001) and reduced the LVEDD (P < 0.05)
in the treatment group compared with the untreated group.
These results indicated that long-term HR reduction by
ivabradine prevented the progression from viral myocarditis
to DCM in mice with chronic viral myocarditis induced by
coxsackievirus B3.
Based on the results of the Western blot, we found
that cytokine levels were upregulated in CVMC-35 mice
compared with the control mice (P < 0.05) and that the
expression of the cytokines TNF-α, IL-1β, and IL-6 in the
ivabradine treatment group was significantly less than in the
untreated CVMC-65 mice (P < 0.001). A number of studies
showed that cytokines play a vital role in tissue fibrosis
(Fairweather et al., 2004; Liu et al., 2006). Gluck et al. (2001)
suggested that the high level of cytokines in chronic viral
myocarditis mice aggravates the damage of connective tissue.
TNF-α increased ECM protein proliferation and induced the
apoptosis and necrosis of myocardial cells, which are ultimately
replaced or repaired by fibrous tissue. IL-6 and IL-1β directly
induce myocardial fibrosis (Pulkki, 1997; Ono et al., 1998;
Abreu et al., 2002; Eriksson et al., 2003). Based on the
previous studies and the present study, we suggest that the
effect of ivabradine on myocardial fibrosis is related to the
reduction of the proinflammatory cytokines TNF-α, IL-1β, and
IL-6.
The present study revealed that ivabradine could significantly
inhibit activation of the p38 MAPK signaling pathway. Mitogen-
activated protein kinase (MAPK) is an important signaling
pathway that participates in multiple cellular processes, including
inflammation, growth, differentiation, cell growth, and cell death
(Clerk and Sugden, 2006). Myocardial hypertrophy, ventricle
remodeling after myocardial infarction, myocardial apoptosis,
inflammation, and atherosclerosis are also accompanied by
activation of the MAPK pathway (Petrich and Wang, 2004;
Streicher et al., 2010). p38 MAPK, one of the MAPK downstream
components, plays an important role in inflammation, fibrosis,
and apoptosis (Li et al., 2005). p38 MAPK could be induced
by the stresses of inflammation, heat-shock protein, ultraviolet
and specific antigen. Streicher et al. (2010) observed that with
the activation of the p38 MAPK pathway, the transcription of
genes for contractility, matrix remodeling, and inflammation
was influenced. The activation of p38 MAPK is a necessary
condition for cardiac remodeling for diabetic cardiomyopathy
(Thandavarayan et al., 2009). Liao et al. (2001) suggested that
normal mice had a better cardiac function than p38 MAPK
transgenic mice. Petrich and Wang (2004) proved that the
p38 pathway regulated the expression of the ECM and the
deteriorated left ventricle remodeling. Based on the above
mentioned studies, the p38 MAPK pathway might take part in
the process of cardiac fibrosis of CVB3-induced chronic viral
myocarditis, and down-regulating the expression of P-p38 might
be helpful for reducing fibrosis, reversing ventricular remodeling
and improving heart function. In this study, no difference was
found in the expression of total-p38 in the five groups. However,
the infected mice had a higher level of expression of P-p38
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compared with the normal control mice. Ivabradine significantly
attenuated the production of P-p38 compared with the untreated
CVMC-65 group (P < 0.05). There was no difference between
the CVMC-65 and CVMC-35 groups in P-p38 production
(P = 0.659).
CONCLUSION
The findings suggest a therapeutic effect of ivabradine
in preventing the progression from viral myocarditis to
DCM in mice with chronic viral myocarditis induced by
coxsackievirus B3, is associated with inhibition of the p38
MAPK pathway, downregulated inflammatory responses and
decreased collagen expression. Ivabradine appears a promising
approach for the treatment of patients with viral myocarditis.
Further experimental and clinical studies are welcome in the
future.
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